Intuitive Surgical -- 8.4/10 -- $452.07

Intuitive Surgical is the undisputed leader in robotic-assisted surgery, commanding ~80% of the global market with 11,106 da Vinci systems installed across hospitals worldwide and over 20 million cumulative procedures performed. The company operates a razor/blade model where approximately 81% of revenue is recurring -- instruments, accessories, and services generate ~$200K+ per installed system annually, making the business highly predictable.

FY2025 was a milestone year. Revenue reached $10.1B (+20.5% YoY), accelerating from 17.2% growth in FY2024. Non-GAAP EPS grew 21.7% to $8.93, marking the third consecutive year of 20%+ EPS growth. Free cash flow nearly doubled to ~$2.5B as the heavy capex cycle from new manufacturing facilities wound down. Procedure growth -- the single most important KPI -- was 18% globally for da Vinci, with total procedures (including Ion) growing 19%.

Da Vinci 5 is the most significant platform upgrade in a decade. FY2025 saw 870 dV5 placements (of 1,721 total), with the installed base reaching 1,232 systems used by 10,000+ surgeons. Key differentiators include Force Feedback (55% reduction in maximum tissue force during suturing), 10,000x computing power enabling AI-powered surgical analytics, and higher utilization rates that already outpace the prior-generation Xi. The MIA+ digital subscription (simulation, Telepresence, Case Insights) creates a new recurring revenue stream with renewals beginning mid-2026.

Ion lung biopsy is a second growth platform approaching halfway penetration of US bronchoscopic biopsy, with early launches in Europe, Korea, China, and Australia. The Ion installed base reached 995 systems with 40,200 procedures in Q4 alone.

International expansion continues to accelerate -- OUS procedures grew 23% in FY2025 and now represent ~35% of global volume. General surgery (cholecystectomy, hernia) is barely penetrated globally. Cardiac surgery (17,000 procedures in FY2025) has a TAM of ~160,000 in cleared geographies with FDA clearance recently received for dV5 cardiac in the US. The refurbished Xi (XiR) program opens ASCs and international greenfield markets at lower price points.

ISRG receives a composite score of 8.4/10, reflecting the strongest robotic surgery franchise in the world with accelerating growth, a generational platform upgrade, and multiple underappreciated growth vectors.

1. Unassailable ecosystem moat. With ~80% global market share, 50,000+ trained surgeons, 11,106 installed systems, and 20M+ cumulative procedures generating the largest surgical dataset in the world, Intuitive has built a flywheel that competitors cannot replicate. The razor/blade model (81% recurring revenue) means each system placement locks in decades of high-margin consumables revenue. Switching costs are enormous -- hospitals invest years in training, workflow integration, and capital equipment.

2. Da Vinci 5 is a re-acceleration catalyst. The generational upgrade is driving higher utilization, expanding clinical applications (Force Feedback enables cardiac and more complex procedures), and creating the MIA+ digital subscription stream. The trade-in cycle also generates XiR inventory for ASC and international greenfield expansion -- a second-order benefit the street underappreciates.

3. International and procedural TAM expansion. Addressable procedures grew from 7M to 9M in two years. OUS procedures grew 23% in FY2025 with general surgery barely penetrated. Cardiac surgery, Ion lung biopsy, and ASC expansion each represent billion-dollar incremental opportunities not fully reflected in consensus estimates.

Bull case: Procedure growth remains in mid-to-high teens as dV5 drives utilization uplift and international expansion accelerates. Force Feedback, cardiac, ASC/XiR, and MIA+ digital subscriptions are incremental growth vectors not fully reflected in consensus. Gross margins recover as dV5 costs come down and facility leverage kicks in. FCF continues to expand, supporting buybacks and innovation.

Bear case: Valuation at 44x forward EPS leaves little margin of safety. Competition from local Chinese robotics companies and eventually Hugo/Ottava could pressure pricing and win rates. Hospital capital budget constraints in a recessionary environment slow the dV5 upgrade cycle. Tariff escalation or Medicaid funding cuts impact procedure volumes. GLP-1 headwinds in bariatrics continue to weigh on I&A per procedure mix.

Key catalysts and monitoring points:

• FY2026 procedure growth trajectory: Management guided 13-15% da Vinci procedure growth for FY2026, well below the 18% delivered in FY2025. Watch for an early raise -- the pattern of sandbagging then raising guidance has repeated for two consecutive years. Any deceleration below 15% would be a negative signal.
• Japan new reimbursement codes (June 2026): Additional robotic procedures expected to receive reimbursement approval. Japan is already a strong market and expanded codes could meaningfully accelerate OUS procedure growth in H2 2026.
• China tender win ratios and system placements: The most significant competitive threat. Provincial tenders increasingly favor domestic suppliers, and ISRG saw lower win ratios in Q4. Track quarterly placements and competitive commentary for signs of share loss.
• MIA+ digital subscription renewal rates (mid-2026): An entirely new recurring revenue stream that most models underappreciate. Early renewal rates and pricing will signal the durability of this high-margin revenue layer.
• Force Feedback broad supply and clinical evidence: Limited supply constrained adoption in FY2025. Broad availability unlocks both clinical value and higher I&A per procedure from premium-priced instruments. Watch for landmark clinical publications validating outcomes.
• Gross margin trajectory: Guided 67-68% for FY2026 with 120bps of tariff headwinds. The path back to 70%+ requires dV5 cost-downs and facility leverage -- achievable but multi-year. Any further compression would pressure the multiple.

For the full analysis, see the Business Model, Financials, and Valuation pages.

Concerns, Catalysts & Risks -- full analysis

Buy at current levels -- this is the highest-quality franchise in MedTech with multiple underappreciated growth vectors, and the 25% pullback from the all-time high provides a reasonable entry point. At ~44x FY2026E non-GAAP EPS ($10.22 consensus), ISRG commands a premium valuation -- but the premium is earned by 20%+ revenue growth, 81% recurring revenue, $9B in cash with no debt, and a competitive moat that has only strengthened over two decades.

The key insight is that consensus estimates likely undercount multiple growth vectors simultaneously: (1) procedure growth guidance of 13-15% has been consistently beaten for two years, (2) cardiac surgery with 160K addressable procedures is not in most models, (3) MIA+ digital subscriptions are a new recurring revenue stream starting mid-2026, (4) ASC/XiR expansion opens an entirely new site-of-care market, and (5) Force Feedback broad supply unlocks premium I&A pricing. Each vector alone is modest, but collectively they represent meaningful upside to consensus.

Key position-sizing considerations: (1) the ~44x forward multiple means any deceleration in procedure growth or margin compression could trigger significant multiple contraction -- this is a name where execution must remain flawless; (2) China competitive dynamics are intensifying and could weigh on international growth; (3) tariff policy remains fluid with 120bps of headwind already guided for FY2026; (4) gross margins at 67-68% are below the historical 70%+ range and the recovery path is multi-year. The quality of the franchise and the breadth of the growth opportunity warrant a Buy, but position sizing should reflect the valuation premium and the elevated bar for execution.